{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:41:42Z","timestamp":1792431702589,"version":"4.5.0"},"reference-count":29,"publisher":"Massachusetts Medical Society","issue":"2","license":[{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nejmgroup.org\/legal\/terms-of-use.htm"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["Contract No. HHSN271201500065C; HHSN271201400028C"],"award-info":[{"award-number":["Contract No. HHSN271201500065C; HHSN271201400028C"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG1DA020024; UG1DA013035; UG1DA040316; UG1DA013727"],"award-info":[{"award-number":["UG1DA020024; UG1DA013035; UG1DA040316; UG1DA013727"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2021,1,14]]},"DOI":"10.1056\/nejmoa2020214","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T17:14:04Z","timestamp":1610558044000},"page":"140-153","source":"Crossref","is-referenced-by-count":265,"title":["Bupropion and Naltrexone in Methamphetamine Use Disorder"],"prefix":"10.1056","volume":"384","author":[{"given":"Madhukar H.","family":"Trivedi","sequence":"first","affiliation":[{"name":"From the Peter O\u2019Donnell Jr. Brain Institute at the University of Texas Southwestern Medical Center (M.H.T.) and the University of Texas Southwestern Medical Center (R.W., A.C., T.C., M.K., K.S.-W., S.W.), Dallas, the University of Texas Health Science Center at Houston, Houston (J.S.), and Texas Tech University, Permian Basin, Odessa (A.J.R.); the University of California, Los Angeles, Los Angeles (W.L., S. Shoptaw); the Emmes Company, Rockville (G.S., A.W.), and the National Institute on Drug..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robrina","family":"Walker","sequence":"additional","affiliation":[{"name":"From the Peter O\u2019Donnell Jr. Brain Institute at the University of Texas Southwestern Medical Center (M.H.T.) and the University of Texas Southwestern Medical Center (R.W., A.C., T.C., M.K., K.S.-W., S.W.), Dallas, the University of Texas Health Science Center at Houston, Houston (J.S.), and Texas Tech University, Permian Basin, Odessa (A.J.R.); the University of California, Los Angeles, Los Angeles (W.L., S. Shoptaw); the Emmes Company, Rockville (G.S., A.W.), and the National Institute on Drug..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Ling","sequence":"additional","affiliation":[{"name":"From the Peter O\u2019Donnell Jr. Brain Institute at the University of Texas Southwestern Medical Center (M.H.T.) and the University of Texas Southwestern Medical Center (R.W., A.C., T.C., M.K., K.S.-W., S.W.), Dallas, the University of Texas Health Science Center at Houston, Houston (J.S.), and Texas Tech University, Permian Basin, Odessa (A.J.R.); the University of California, Los Angeles, Los Angeles (W.L., S. Shoptaw); the Emmes Company, Rockville (G.S., A.W.), and the National Institute on Drug..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriane","family":"dela Cruz","sequence":"additional","affiliation":[{"name":"From the Peter O\u2019Donnell Jr. Brain Institute at the University of Texas Southwestern Medical Center (M.H.T.) and the University of Texas Southwestern Medical Center (R.W., A.C., T.C., M.K., K.S.-W., S.W.), Dallas, the University of Texas Health Science Center at Houston, Houston (J.S.), and Texas Tech University, Permian Basin, Odessa (A.J.R.); the University of California, Los Angeles, Los Angeles (W.L., S. Shoptaw); the Emmes Company, Rockville (G.S., A.W.), and the National Institute on Drug..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Sharma","sequence":"additional","affiliation":[{"name":"From the Peter O\u2019Donnell Jr. Brain Institute at the University of Texas Southwestern Medical Center (M.H.T.) and the University of Texas Southwestern Medical Center (R.W., A.C., T.C., M.K., K.S.-W., S.W.), Dallas, the University of Texas Health Science Center at Houston, Houston (J.S.), and Texas Tech University, Permian Basin, Odessa (A.J.R.); the University of California, Los Angeles, Los Angeles (W.L., S. Shoptaw); the Emmes Company, Rockville (G.S., A.W.), and the National Institute on Drug..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Carmody","sequence":"additional","affiliation":[{"name":"From the Peter O\u2019Donnell Jr. Brain Institute at the University of Texas Southwestern Medical Center (M.H.T.) and the University of Texas Southwestern Medical Center (R.W., A.C., T.C., M.K., K.S.-W., S.W.), Dallas, the University of Texas Health Science Center at Houston, Houston (J.S.), and Texas Tech University, Permian Basin, Odessa (A.J.R.); the University of California, Los Angeles, Los Angeles (W.L., S. Shoptaw); the Emmes Company, Rockville (G.S., A.W.), and the National Institute on Drug..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udi E.","family":"Ghitza","sequence":"additional","affiliation":[{"name":"From the Peter O\u2019Donnell Jr. Brain Institute at the University of Texas Southwestern Medical Center (M.H.T.) and the University of Texas Southwestern Medical Center (R.W., A.C., T.C., M.K., K.S.-W., S.W.), Dallas, the University of Texas Health Science Center at Houston, Houston (J.S.), and Texas Tech University, Permian Basin, Odessa (A.J.R.); the University of California, Los Angeles, Los Angeles (W.L., S. Shoptaw); the Emmes Company, Rockville (G.S., A.W.), and the National Institute on Drug..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Wahle","sequence":"additional","affiliation":[{"name":"From the Peter O\u2019Donnell Jr. Brain Institute at the University of Texas Southwestern Medical Center (M.H.T.) and the University of Texas Southwestern Medical Center (R.W., A.C., T.C., M.K., K.S.-W., S.W.), Dallas, the University of Texas Health Science Center at Houston, Houston (J.S.), and Texas Tech University, Permian Basin, Odessa (A.J.R.); the University of California, Los Angeles, Los Angeles (W.L., S. Shoptaw); the Emmes Company, Rockville (G.S., A.W.), and the National Institute on Drug..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mora","family":"Kim","sequence":"additional","affiliation":[{"name":"From the Peter O\u2019Donnell Jr. Brain Institute at the University of Texas Southwestern Medical Center (M.H.T.) and the University of Texas Southwestern Medical Center (R.W., A.C., T.C., M.K., K.S.-W., S.W.), Dallas, the University of Texas Health Science Center at Houston, Houston (J.S.), and Texas Tech University, Permian Basin, Odessa (A.J.R.); the University of California, Los Angeles, Los Angeles (W.L., S. Shoptaw); the Emmes Company, Rockville (G.S., A.W.), and the National Institute on Drug..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Shores-Wilson","sequence":"additional","affiliation":[{"name":"From the Peter O\u2019Donnell Jr. Brain Institute at the University of Texas Southwestern Medical Center (M.H.T.) and the University of Texas Southwestern Medical Center (R.W., A.C., T.C., M.K., K.S.-W., S.W.), Dallas, the University of Texas Health Science Center at Houston, Houston (J.S.), and Texas Tech University, Permian Basin, Odessa (A.J.R.); the University of California, Los Angeles, Los Angeles (W.L., S. Shoptaw); the Emmes Company, Rockville (G.S., A.W.), and the National Institute on Drug..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Sparenborg","sequence":"additional","affiliation":[{"name":"From the Peter O\u2019Donnell Jr. Brain Institute at the University of Texas Southwestern Medical Center (M.H.T.) and the University of Texas Southwestern Medical Center (R.W., A.C., T.C., M.K., K.S.-W., S.W.), Dallas, the University of Texas Health Science Center at Houston, Houston (J.S.), and Texas Tech University, Permian Basin, Odessa (A.J.R.); the University of California, Los Angeles, Los Angeles (W.L., S. Shoptaw); the Emmes Company, Rockville (G.S., A.W.), and the National Institute on Drug..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Coffin","sequence":"additional","affiliation":[{"name":"From the Peter O\u2019Donnell Jr. Brain Institute at the University of Texas Southwestern Medical Center (M.H.T.) and the University of Texas Southwestern Medical Center (R.W., A.C., T.C., M.K., K.S.-W., S.W.), Dallas, the University of Texas Health Science Center at Houston, Houston (J.S.), and Texas Tech University, Permian Basin, Odessa (A.J.R.); the University of California, Los Angeles, Los Angeles (W.L., S. Shoptaw); the Emmes Company, Rockville (G.S., A.W.), and the National Institute on Drug..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Schmitz","sequence":"additional","affiliation":[{"name":"From the Peter O\u2019Donnell Jr. Brain Institute at the University of Texas Southwestern Medical Center (M.H.T.) and the University of Texas Southwestern Medical Center (R.W., A.C., T.C., M.K., K.S.-W., S.W.), Dallas, the University of Texas Health Science Center at Houston, Houston (J.S.), and Texas Tech University, Permian Basin, Odessa (A.J.R.); the University of California, Los Angeles, Los Angeles (W.L., S. Shoptaw); the Emmes Company, Rockville (G.S., A.W.), and the National Institute on Drug..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Wiest","sequence":"additional","affiliation":[{"name":"From the Peter O\u2019Donnell Jr. Brain Institute at the University of Texas Southwestern Medical Center (M.H.T.) and the University of Texas Southwestern Medical Center (R.W., A.C., T.C., M.K., K.S.-W., S.W.), Dallas, the University of Texas Health Science Center at Houston, Houston (J.S.), and Texas Tech University, Permian Basin, Odessa (A.J.R.); the University of California, Los Angeles, Los Angeles (W.L., S. Shoptaw); the Emmes Company, Rockville (G.S., A.W.), and the National Institute on Drug..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Bart","sequence":"additional","affiliation":[{"name":"From the Peter O\u2019Donnell Jr. Brain Institute at the University of Texas Southwestern Medical Center (M.H.T.) and the University of Texas Southwestern Medical Center (R.W., A.C., T.C., M.K., K.S.-W., S.W.), Dallas, the University of Texas Health Science Center at Houston, Houston (J.S.), and Texas Tech University, Permian Basin, Odessa (A.J.R.); the University of California, Los Angeles, Los Angeles (W.L., S. Shoptaw); the Emmes Company, Rockville (G.S., A.W.), and the National Institute on Drug..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan C.","family":"Sonne","sequence":"additional","affiliation":[{"name":"From the Peter O\u2019Donnell Jr. Brain Institute at the University of Texas Southwestern Medical Center (M.H.T.) and the University of Texas Southwestern Medical Center (R.W., A.C., T.C., M.K., K.S.-W., S.W.), Dallas, the University of Texas Health Science Center at Houston, Houston (J.S.), and Texas Tech University, Permian Basin, Odessa (A.J.R.); the University of California, Los Angeles, Los Angeles (W.L., S. Shoptaw); the Emmes Company, Rockville (G.S., A.W.), and the National Institute on Drug..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidarth","family":"Wakhlu","sequence":"additional","affiliation":[{"name":"From the Peter O\u2019Donnell Jr. Brain Institute at the University of Texas Southwestern Medical Center (M.H.T.) and the University of Texas Southwestern Medical Center (R.W., A.C., T.C., M.K., K.S.-W., S.W.), Dallas, the University of Texas Health Science Center at Houston, Houston (J.S.), and Texas Tech University, Permian Basin, Odessa (A.J.R.); the University of California, Los Angeles, Los Angeles (W.L., S. Shoptaw); the Emmes Company, Rockville (G.S., A.W.), and the National Institute on Drug..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. John","family":"Rush","sequence":"additional","affiliation":[{"name":"From the Peter O\u2019Donnell Jr. Brain Institute at the University of Texas Southwestern Medical Center (M.H.T.) and the University of Texas Southwestern Medical Center (R.W., A.C., T.C., M.K., K.S.-W., S.W.), Dallas, the University of Texas Health Science Center at Houston, Houston (J.S.), and Texas Tech University, Permian Basin, Odessa (A.J.R.); the University of California, Los Angeles, Los Angeles (W.L., S. Shoptaw); the Emmes Company, Rockville (G.S., A.W.), and the National Institute on Drug..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward V.","family":"Nunes","sequence":"additional","affiliation":[{"name":"From the Peter O\u2019Donnell Jr. Brain Institute at the University of Texas Southwestern Medical Center (M.H.T.) and the University of Texas Southwestern Medical Center (R.W., A.C., T.C., M.K., K.S.-W., S.W.), Dallas, the University of Texas Health Science Center at Houston, Houston (J.S.), and Texas Tech University, Permian Basin, Odessa (A.J.R.); the University of California, Los Angeles, Los Angeles (W.L., S. Shoptaw); the Emmes Company, Rockville (G.S., A.W.), and the National Institute on Drug..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Shoptaw","sequence":"additional","affiliation":[{"name":"From the Peter O\u2019Donnell Jr. Brain Institute at the University of Texas Southwestern Medical Center (M.H.T.) and the University of Texas Southwestern Medical Center (R.W., A.C., T.C., M.K., K.S.-W., S.W.), Dallas, the University of Texas Health Science Center at Houston, Houston (J.S.), and Texas Tech University, Permian Basin, Odessa (A.J.R.); the University of California, Los Angeles, Los Angeles (W.L., S. Shoptaw); the Emmes Company, Rockville (G.S., A.W.), and the National Institute on Drug..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","first-page":"1","article-title":"Regional differences in the drugs most frequently involved in drug overdose deaths: United States, 2017","volume":"68","author":"Hedegaard H","year":"2019","unstructured":"Hedegaard H, Bastian BA, Trinidad JP, Spencer MR, Warner M. Regional differences in the drugs most frequently involved in drug overdose deaths: United States, 2017. Natl Vital Stat Rep 2019;68:1-16.32501207","journal-title":"Natl Vital Stat Rep"},{"key":"e_1_3_5_3_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drugalcdep.2018.08.029","article-title":"Twin epidemics: the surging rise of methamphetamine use in chronic opioid users.","volume":"193","author":"Ellis MS","year":"2018","unstructured":"Ellis MS, Kasper ZA, Cicero TJ. Twin epidemics: the surging rise of methamphetamine use in chronic opioid users. Drug Alcohol Depend 2018;193:14-20.30326396","journal-title":"Drug Alcohol Depend"},{"key":"e_1_3_5_4_2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1001\/jamapsychiatry.2017.0135","article-title":"Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine: a systematic review and meta-analysis.","volume":"74","author":"Ashok AH","year":"2017","unstructured":"Ashok AH, Mizuno Y, Volkow ND, Howes OD. Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine: a systematic review and meta-analysis. JAMA Psychiatry 2017;74:511-519.28297025","journal-title":"JAMA Psychiatry"},{"key":"e_1_3_5_5_2","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1080\/14656566.2019.1681970","article-title":"Pharmacotherapeutic strategies for methamphetamine use disorder: mind the subgroups.","volume":"20","author":"Soares E","year":"2019","unstructured":"Soares E, Pereira FC. Pharmacotherapeutic strategies for methamphetamine use disorder: mind the subgroups. Expert Opin Pharmacother 2019;20:2273-2293.31671001","journal-title":"Expert Opin Pharmacother"},{"key":"e_1_3_5_6_2","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/sj.npp.1301481","article-title":"Bupropion for the treatment of methamphetamine dependence.","volume":"33","author":"Elkashef AM","year":"2008","unstructured":"Elkashef AM, Rawson RA, Anderson AL, et al. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology 2008;33:1162-1170.17581531","journal-title":"Neuropsychopharmacology"},{"key":"e_1_3_5_7_2","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1111\/add.12636","article-title":"Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use.","volume":"109","author":"Heinzerling KG","year":"2014","unstructured":"Heinzerling KG, Swanson A-N, Hall TM, Yi Y, Wu Y, Shoptaw SJ. Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use. Addiction 2014;109:1878-1886.24894963","journal-title":"Addiction"},{"key":"e_1_3_5_8_2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.drugalcdep.2015.01.036","article-title":"Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial.","volume":"150","author":"Anderson AL","year":"2015","unstructured":"Anderson AL, Li S-H, Markova D, et al. Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 2015;150:170-174.25818061","journal-title":"Drug Alcohol Depend"},{"key":"e_1_3_5_9_2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/ADM.0000000000000297","article-title":"Extended-release injectable naltrexone (XR-NTX) with intensive psychosocial therapy for amphetamine-dependent persons seeking treatment: a placebo-controlled trial.","volume":"11","author":"Runarsdottir V","year":"2017","unstructured":"Runarsdottir V, Hansdottir I, Tyrfingsson T, et al. Extended-release injectable naltrexone (XR-NTX) with intensive psychosocial therapy for amphetamine-dependent persons seeking treatment: a placebo-controlled trial. J Addict Med 2017;11:197-204.28379861","journal-title":"J Addict Med"},{"key":"e_1_3_5_10_2","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1176\/appi.ajp.2008.08020304","article-title":"Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial.","volume":"165","author":"Jayaram-Lindstr\u00f6m N","year":"2008","unstructured":"Jayaram-Lindstr\u00f6m N, Hammarberg A, Beck O, Franck J. Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am J Psychiatry 2008;165:1442-1448.18765480","journal-title":"Am J Psychiatry"},{"key":"e_1_3_5_11_2","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1038\/npp.2015.83","article-title":"The effects of naltrexone on subjective response to methamphetamine in a clinical sample: a double-blind, placebo-controlled laboratory study.","volume":"40","author":"Ray LA","year":"2015","unstructured":"Ray LA, Bujarski S, Courtney KE, et al. The effects of naltrexone on subjective response to methamphetamine in a clinical sample: a double-blind, placebo-controlled laboratory study. Neuropsychopharmacology 2015;40:2347-2356.25801501","journal-title":"Neuropsychopharmacology"},{"key":"e_1_3_5_12_2","first-page":"305","article-title":"Pharmacological treatments for methamphetamine addiction: current status and future directions.","volume":"10","author":"Ballester J","year":"2017","unstructured":"Ballester J, Valentine G, Sofuoglu M. Pharmacological treatments for methamphetamine addiction: current status and future directions. Expert Rev Clin Pharmacol 2017;10:305-314.27927042","journal-title":"Expert Rev Clin Pharmacol"},{"key":"e_1_3_5_13_2","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1111\/add.14755","article-title":"Pharmacotherapy for methamphetamine\/amphetamine use disorder \u2014 a systematic review and meta-analysis.","volume":"114","author":"Chan B","year":"2019","unstructured":"Chan B, Freeman M, Kondo K, et al. Pharmacotherapy for methamphetamine\/amphetamine use disorder \u2014 a systematic review and meta-analysis. Addiction 2019;114:2122-2136.31328345","journal-title":"Addiction"},{"key":"e_1_3_5_14_2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40263-020-00711-x","article-title":"Pharmacological treatment of methamphetamine\/amphetamine dependence: a systematic review.","volume":"34","author":"Siefried KJ","year":"2020","unstructured":"Siefried KJ, Acheson LS, Lintzeris N, Ezard N. Pharmacological treatment of methamphetamine\/amphetamine dependence: a systematic review. CNS Drugs 2020;34:337-365.32185696","journal-title":"CNS Drugs"},{"key":"e_1_3_5_15_2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/FBP.0000000000000224","article-title":"Methamphetamine-like discriminative stimulus effects of bupropion and its two hydroxy metabolites in male rhesus monkeys.","volume":"27","author":"Banks ML","year":"2016","unstructured":"Banks ML, Smith DA, Blough BE. Methamphetamine-like discriminative stimulus effects of bupropion and its two hydroxy metabolites in male rhesus monkeys. Behav Pharmacol 2016;27:196-203.26886209","journal-title":"Behav Pharmacol"},{"key":"e_1_3_5_16_2","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/sj.npp.1300979","article-title":"Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving.","volume":"31","author":"Newton TF","year":"2006","unstructured":"Newton TF, Roache JD, De La Garza R II, et al. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 2006;31:1537-1544.16319910","journal-title":"Neuropsychopharmacology"},{"key":"e_1_3_5_17_2","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40263-016-0373-0","article-title":"Naltrexone: a pan-addiction treatment?","volume":"30","author":"Aboujaoude E","year":"2016","unstructured":"Aboujaoude E, Salame WO. Naltrexone: a pan-addiction treatment? CNS Drugs 2016;30:719-733.27401883","journal-title":"CNS Drugs"},{"key":"e_1_3_5_18_2","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/adb.12425","article-title":"Effects of naltrexone on alcohol self-administration and craving: meta-analysis of human laboratory studies.","volume":"22","author":"Hendershot CS","year":"2017","unstructured":"Hendershot CS, Wardell JD, Samokhvalov AV, Rehm J. Effects of naltrexone on alcohol self-administration and craving: meta-analysis of human laboratory studies. Addict Biol 2017;22:1515-1527.27411969","journal-title":"Addict Biol"},{"key":"e_1_3_5_19_2","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1007\/s00213-017-4607-8","article-title":"Naltrexone moderates the relationship between cue-induced craving and subjective response to methamphetamine in individuals with methamphetamine use disorder.","volume":"234","author":"Roche DJO","year":"2017","unstructured":"Roche DJO, Worley MJ, Courtney KE, et al. Naltrexone moderates the relationship between cue-induced craving and subjective response to methamphetamine in individuals with methamphetamine use disorder. Psychopharmacology (Berl) 2017;234:1997-2007.28357460","journal-title":"Psychopharmacology (Berl)"},{"key":"e_1_3_5_20_2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/ADM.0000000000000218","article-title":"Utilizing a two-stage design to investigate the safety and potential efficacy of monthly naltrexone plus once-daily bupropion as a treatment for methamphetamine use disorder.","volume":"10","author":"Mooney LJ","year":"2016","unstructured":"Mooney LJ, Hillhouse MP, Thomas C, et al. Utilizing a two-stage design to investigate the safety and potential efficacy of monthly naltrexone plus once-daily bupropion as a treatment for methamphetamine use disorder. J Addict Med 2016;10:236-243.27379819","journal-title":"J Addict Med"},{"key":"e_1_3_5_21_2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000069738","article-title":"The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach.","volume":"72","author":"Fava M","year":"2003","unstructured":"Fava M, Evins AE, Dorer DJ, Schoenfeld DA. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom 2003;72:115-127.12707478","journal-title":"Psychother Psychosom"},{"key":"e_1_3_5_22_2","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.cct.2011.04.006","article-title":"Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials.","volume":"32","author":"Chen Y-F","year":"2011","unstructured":"Chen Y-F, Yang Y, Hung HMJ, Wang S-J. Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials. Contemp Clin Trials 2011;32:592-604.21540126","journal-title":"Contemp Clin Trials"},{"key":"e_1_3_5_23_2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/1740774507081217","article-title":"An examination of the efficiency of the sequential parallel design in psychiatric clinical trials.","volume":"4","author":"Tamura RN","year":"2007","unstructured":"Tamura RN, Huang X. An examination of the efficiency of the sequential parallel design in psychiatric clinical trials. Clin Trials 2007;4:309-317.17848492","journal-title":"Clin Trials"},{"key":"e_1_3_5_24_2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.drugalcdep.2014.10.002","article-title":"Assessing craving and its relationship to subsequent prescription opioid use among treatment-seeking prescription opioid dependent patients.","volume":"145","author":"McHugh RK","year":"2014","unstructured":"McHugh RK, Fitzmaurice GM, Carroll KM, et al. Assessing craving and its relationship to subsequent prescription opioid use among treatment-seeking prescription opioid dependent patients. Drug Alcohol Depend 2014;145:121-126.25454409","journal-title":"Drug Alcohol Depend"},{"key":"e_1_3_5_25_2","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure.","volume":"16","author":"Kroenke K","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001;16:606-613.11556941","journal-title":"J Gen Intern Med"},{"key":"e_1_3_5_26_2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/SAR.S38902","article-title":"The Treatment Effectiveness Assessment (TEA): an efficient, patient-centered instrument for evaluating progress in recovery from addiction.","volume":"3","author":"Ling W","year":"2012","unstructured":"Ling W, Farabee D, Liepa D, Wu L-T. The Treatment Effectiveness Assessment (TEA): an efficient, patient-centered instrument for evaluating progress in recovery from addiction. Subst Abuse Rehabil 2012;3:129-136.23580868","journal-title":"Subst Abuse Rehabil"},{"key":"e_1_3_5_27_2","doi-asserted-by":"crossref","first-page":"765","DOI":"10.4088\/JCP.11m06840","article-title":"Concise Associated Symptoms Tracking Scale: a brief self-report and clinician rating of symptoms associated with suicidality.","volume":"72","author":"Trivedi MH","year":"2011","unstructured":"Trivedi MH, Wisniewski SR, Morris DW, et al. Concise Associated Symptoms Tracking Scale: a brief self-report and clinician rating of symptoms associated with suicidality. J Clin Psychiatry 2011;72:765-774.21733477","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_5_28_2","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1002\/sim.5728","article-title":"A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies.","volume":"32","author":"Doros G","year":"2013","unstructured":"Doros G, Pencina M, Rybin D, Meisner A, Fava M. A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies. Stat Med 2013;32:2767-2789.23355369","journal-title":"Stat Med"},{"key":"e_1_3_5_29_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.drugalcdep.2014.08.003","article-title":"Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature.","volume":"143","author":"Courtney KE","year":"2014","unstructured":"Courtney KE, Ray LA. Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature. Drug Alcohol Depend 2014;143:11-21.25176528","journal-title":"Drug Alcohol Depend"},{"key":"e_1_3_5_30_2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.drugalcdep.2012.11.016","article-title":"Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings.","volume":"129","author":"Panenka WJ","year":"2013","unstructured":"Panenka WJ, Procyshyn RM, Lecomte T, et al. Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend 2013;129:167-179.23273775","journal-title":"Drug Alcohol Depend"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2020214","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T20:34:02Z","timestamp":1711485242000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2020214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,14]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,1,14]]}},"alternative-id":["10.1056\/NEJMoa2020214"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa2020214","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,14]]}}}